ImmuCell Reports 28.4% Increase in Q1 2026 Product Sales

Animal health company sees strong domestic demand for its Tri-Shield First Defense product line.

Apr. 9, 2026 at 2:37am

Got story updates? Submit your updates here. ›

A photorealistic studio still-life photograph featuring a polished, geometric glass bottle filled with a vibrant blue-green liquid, symbolizing the advanced animal health biologics produced by ImmuCell. The bottle is placed on a clean, monochromatic background with dramatic lighting and shadows, conveying the premium quality and scientific precision of the company's products.ImmuCell's innovative animal health products, like its Tri-Shield First Defense line, are driving the company's strong sales growth in the first quarter of 2026.Portland Today

ImmuCell Corporation, an animal health biologics company, announced preliminary, unaudited sales results for the first quarter of 2026. Total sales for the three-month period ended March 31, 2026 were $10.4 million, a 28.4% increase compared to the same period in 2025. Domestic sales were $9.7 million, a 35.7% increase, while international sales declined 30.2% to $0.6 million. The company's Tri-Shield First Defense product line saw a 38.5% increase in sales to $7.9 million.

Why it matters

ImmuCell's strong first quarter results demonstrate the growing demand for its scours prevention products, particularly its flagship Tri-Shield First Defense line, which provides broad protection for dairy and beef calves. The company's focus on expanding its commercial team and inventory strategies appears to be paying off as it seeks to gain market share in the competitive animal health market.

The details

ImmuCell attributed the sales growth to strong seasonal demand from the cow-calf segment, which is typically less price sensitive and seeks the broadest protection for calves. The company said it was well-prepared to meet this demand during the peak selling season of November through February. However, the company noted that its previous backorder situation continues to create challenges in predicting and explaining growth rates.

  • Total sales for the three-month period ended March 31, 2026 were $10.4 million.
  • Domestic sales were $9.7 million in 2026, a 35.7% increase compared to 2025.
  • International sales were $0.6 million in 2026, a 30.2% decline compared to 2025.
  • Tri-Shield First Defense sales were $7.9 million in 2026, a 38.5% increase compared to 2025.

The players

ImmuCell Corporation

An animal health biologics company that develops, manufactures and markets products to improve calf health and productivity.

Olivier te Boekhorst

President and CEO of ImmuCell.

Timothy C. Fiori

Chief Financial Officer of ImmuCell.

Bobbi Jo Brockmann

Senior Vice President, Sales and Marketing of ImmuCell.

Got photos? Submit your photos here. ›

What they’re saying

“We had outstanding first quarter sales performance driven by our Tri-Shield® product. This gives us confidence that our strategy of focusing on First Defense® is working. We entered the year targeting growth and market share gains in scours solutions, and our team was well-prepared to meet demand during our peak season with new inventory and manufacturing strategies in place.”

— Olivier te Boekhorst, President and CEO

“First quarter results were driven by seasonal demand from the cow-calf segment that is typically less price sensitive and seeks the broadest protection. This plays to the strengths of Tri-Shield® and explains why November through February is our peak selling season.”

— Timothy C. Fiori, Chief Financial Officer

“As we move into the second and third quarters, demand shifts toward our year-round dairy customers. We are focused on new customer acquisition within that segment, supported by the expansion of our commercial team. We are pleased to announce we have hired a leader for our international commercial efforts and two domestic field sales managers to support our growth.”

— Bobbi Jo Brockmann, Senior Vice President, Sales and Marketing

What’s next

The company is planning to host a conference call on Friday, May 15, 2026 at 9:00 AM ET to discuss the unaudited financial results for the quarter ended March 31, 2026.

The takeaway

ImmuCell's strong first quarter performance, driven by robust domestic demand for its Tri-Shield First Defense product line, demonstrates the company's ability to capitalize on the growing need for effective calf health solutions in the dairy and beef industries. The expansion of its commercial team and inventory strategies position ImmuCell for continued growth as it seeks to gain market share and serve its year-round dairy customers.